[et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″ global_colors_info=”{}”][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.10.7″ _module_preset=”default” text_orientation=”justified” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]
However, an expert cautions that this test should be considered as being under clinical investigation. Providence Health System, based in Renton, Washington, will be the first health system in the US to offer access to the Galleri test, where it will be available as a complement to recommended single-cancer screening tests....medscape.com, Blood Test for 50 Cancers Coming to US Clinics Soon, Roxanne Nelson, RN, BSN, 2021
“The blood test, which will be prescription only, will be available initially through innovative partner health systems like Providence, as well as medical practices, and self-insured employers,” said Leigh Strope, director of corporate communications at GRAIL.
“Providence’s vision is to integrate compelling diagnostic solutions like the Galleri test into clinical care to help drive earlier detection to try to improve and save lives,” she said.
On its website, GRAIL notes that the Galleri blood test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. It is intended to detect cancer signals and to predict where in the body the cancer signal is located.
[/et_pb_text][et_pb_button button_url=”https://www.medscape.com/viewarticle/951268?src=WNL_mdpls_210521_mscpedit_wir&uac=121194DG&spon=17&impID=3389698&faf=1″ url_new_window=”on” button_text=”Full Article” _builder_version=”4.10.7″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][/et_pb_button][/et_pb_column][/et_pb_row][/et_pb_section]